October 4, 2023
Moderna’s combo vaccine shows strong immunogenicity against influenza and COVID-19
Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Moderna
November 14, 2022
Moderna’s biovalent booster candidates meet primary endpoint of superiority against Omicron variants in trai
Moderna said Monday that both of its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared…
October 12, 2022
Merck and Moderna take option by Merck for joint development dealing of investigational personalized cancer vaccine
Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.
April 20, 2022
Moderna: Clinical update on bivalent COVID-19 booster platform
Moderna has announced new clinical data on its bivalent COVID-19 booster platform including data on the company’s first bivalent booster candidate, mRNA-1273.211, which includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants of concern including Omicron.
April 14, 2022
Moderna and Thermo Fisher Scientific Honored for COVID-19 Vaccine Efforts
The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally, were named “Clinical Research Team of the Year” during the 2021 Citeline Awards.
April 11, 2022
Jorge Gomez Joins Moderna as Chief Financial Officer
Moderna, Inc., (Nasdaq:MRNA) has announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna’s Executive Committee and report to Chief Executive Officer, Stéphane Bancel.
April 11, 2022
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
Moderna, Inc. (NASDAQ:MRNA), has announced the first participants have been dosed in the Phase 1/2 study of the company’s seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030.
April 7, 2022
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats.
April 4, 2022
Moderna Launches New Charitable Foundation to Promote Public Health
Moderna, Inc. (NASDAQ:MRNA), has launched the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populations.
March 29, 2022
FDA Approves Moderna’s Second Booster
Moderna, Inc. (NASDAQ:MRNA) has received approval from the U.S. Food and Drug Administration (FDA) for its amendment to the emergency use authorization (EUA) to allow for a second booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise.